HIV-Associated Neurocognitive Disorders

個数:
電子版価格
¥41,116
  • 電子版あり

HIV-Associated Neurocognitive Disorders

  • 在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
    通常6~9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合がございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Paperback:紙装版/ペーパーバック版/ページ数 652 p.
  • 言語 ENG
  • 商品コード 9780323997447
  • DDC分類 616.83

Full Description

HIV-Associated Neurocognitive Disorders (HAND) presents a complex and evolving challenge in the context of HIV-1 infection and treatment. This comprehensive volume dives into the clinical manifestations, molecular and cellular mechanisms, and therapeutic strategies underlying HAND and its associated comorbidities. This book brings together cutting-edge research and clinical insights, making it an essential resource for researchers, clinicians, and students engaged in HIV-related studies and neurocognitive research. This resource also aims to advance our understanding of HAND to contribute to the development of novel diagnostic tools and therapeutic interventions for improved patient outcomes.

Contents

1. An overview of the mechanisms of HIV-1 infection, latency, pathogenesis, and eradication strategies from the CNS
2. Central Nervous System Complications of Human Immunodeficiency Virus Infection
3. Health LIteracy in HIV-associated Neurocognitive Disorders
4. Neuroimaging insights into the CNS effects of HIV infection
5. Early and upstream subcellular organellar events associated with HAND
6. White matter loss and oligodendrocyte dysfunction in HAND
7. Pathogenesis of HIV-associated pain
8. Neuropathogenesis of HIV-associated neuropathic pain
9. Neuropathic Pain in HIV and the role of the Autophagy pathway
10. Host peripheral immune dynamics increase HIV-associated neurocognitive disorders incidence and progression
11. The role of immunometabolism in HIV associated depression and cognitive impairment
12. Role of extracellular viral regulatory proteins in neuropathogenesis
13. Role of inflammasomes in HIV-1 and drug abuse-mediated neuroinflammation
14. The Contribution of Myeloid Cells to HIV Neuropathogenesis
15. Immunophilin ligands modulate phagocytosis and viral replication in HIV-infected macrophages
16. Immunometabolic mechanisms of HIV-associated neurocognitive disorders and traumatic brain injury: Commonalities and contrasts between chronic and acute neurodegenerative pathologies
17. Endolysosome dysfunction in HAND
18. Evolving biomarkers for HIV-associated neurocognitive disorders (HAND)
19. Intracellular immunity against HIV infection
20. NeuroHIV and the Glymphatic System
21. The p75 neurotrophin receptor: emerging role in the pathogenesis of mature synapses in Human Immunodeficiency Virus-Associated Neurocognitive Disorders
22. The Role of HIV-Associated Neuroendocrine Dysfunction in HAND
23. Impact of SARS-CoV-2/COVID-19 on HIV-1-associated neurocognitive disorders
24. Molecular mechanisms of dopaminergic transmission in NeuroHIV
25. The effect of substance misuse on HIV persistence in the CNS: epidemiological, immunological, and molecular considerations
26. Extracellular vesicles in alcohol- and tobacco-induced neuroAIDS
27. NeuroHIV in the context of opioid use disorder: A complex and evolving relationship
28. Impairment of cholesterol homeostasis induced by Nef-containing extracellular vesicles as a factor in HAND pathogenesis
29. Long noncoding RNAs in immune response, viral infection, and opioid use
30. Using cross-species behavioral tools to determine mechanisms contributing to HIV associated neurological disorders and comorbid substance use
31. Therapeutic potential of Curcumin in treating HIV-1 associated neurocognitive disorders
32. Targeting the Endocannabinoid System in HAND
33. Predicting the effectiveness of combination treatment of Dolutegravir and Fluoxetine for Depressive disorders in HIV
34. ANTIRETROVIRAL THERAPY AND ITS CEREBRAL VASCULAR TOXICITY
35. Strategies for HIV-1 Elimination

最近チェックした商品